Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma

Cancer

Volumn 88, Issue 2, 2000, Pages 416-424

  Halvorsen, Ole J ^a,b   Høstmark, Jens ^a   Haukaas, Svein ^a   Hoøisæter, Per Å ^a   Akslen, Lars A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

CDK4; Flow cytometry; P16; Prognosis; Prostate carcinoma; Protein; Radical prostatectomy

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0034650587     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(20000115)88:2<416::aid-cncr24>3.0.co;2-%23     Document Type: Article

References (49)

1. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
2. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
4. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16(CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
5. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J. Mutational analysis of CDKN2 (CDK41/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 1995; 86:622-5.
6. Park DJ, Wilczynski SP, Pham EY, Miller CW, Koeffler HP. Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol 1997;157:1995-9.
7. Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FMJ, Schalken JA. p16 mutations/deletions are not frequent events in prostate cancer. Br J Cancer 1996;74:120-2.
8. Chen W, Weghorst CM, Sabourin CLK, Wang Y, Wang D, Bostwick DG, et al. Abscence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996;12:2603-7.
9. Gaddipati JP, McLeod DG, Sesterhenn IA, Hussussian CJ, Tong YA, Seth P, et al. Mutations of the p16 gene product are rare in prostate cancer. Prostate 1997;30:188-94.
10. INK4A/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997; 3:1889-97.
11. Mangold KA, Takahashi H, Brandigi C, Wada T, Wakui S, Furusato M, et al. p16 (CDKN2/MTS1) gene deletions are rare in prostate carcinomas in the United States and Japan. J Urol 1997;157:1117-20.
12. Jarrard DF, Steven Bova G, Ewing CM, Pin SS, Nguyen SH, Baylin SB, et al. Deletional, mutational, and methylation analyses of CDKN2(p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosom Cancer 1997;19:90-6.
13. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
14. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11.
15. INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870-5.
16. Reed JA, Loganzo F Jr., Shea CR, Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-8.
17. INK4 gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol 1996;8:107-12.
18. Halvorsen OJ, Haukaas S, Høisæeter PÅ, Akslen LA. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urol Oncol 1997;3:59-66.
19. INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74:57-63.
20. Ohhara M, Esumi M, Kurosu Y. Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. Biochem Biophys Res Commun 1996;226:791-5.
21. Hermanek P, Sobin LH, editors. Prostate. UICC TNM classification of malignant tumours. 4th edition. 2nd revision. Berlin: Springer-Verlag, 1992:141-4.
22. Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. (International Histological Classification of Tumours No. 22). Geneva: World Health Organization, 1980.
23. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
24. Mørkve O. Long-term storage of nuclear suspensions prepared from paraffin-embedded material for flow cytometric DNA analysis. Anal Cell Pathol 1990;2:327-31.
25. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45:450-6.
26. Mørkve O, Laerum OD. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas. Cytometry 1991; 12:438-44.
27. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
28. Hu Y-X, Watanebe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-7.
29. Zhao P, Wang DW, Li G, Gao Y, Li X. Abnormal location of p16 protein and overexpression of p53 protein in human radiation-induced skin cancer. J Environ Pathol Toxicol Oncol 1995;14:25-8.
30. INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250-6.
31. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998;78:1661-8.
32. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, et al. The P16-cyclinD/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5474-83.
33. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, et al. Inactivation of p16/CDKN2 and p15MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996;69:466-70.
34. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, et al. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 1997;4:95-102.
35. Chen YJ, Shih LS, Chen YMA. Quantitative analysis of CDKN2, p53 and retinoblastoma mRNA in human gastric carcinoma. Int J Oncol 1998;13:249-54.
36. INK4A in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998;16:2723-7.
37. WAF1/CIPI in human brain tumors. Oncogene 1995;11:2021-8.
38. WAF1/CIPI in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996;180:122-8.
39. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9.
40. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-6.
41. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostate adenocarcinomas. Prostate 1995;26:35-9.
42. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, et al. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995;27:314-20.
43. Ito Y, Kobayashi T, Takeda T, Nakano Y, Tamaki Y, Komoike Y, et al. Expression of p16 and cyclin-dependent kinase 4 proteins in primary breast carcinomas. Oncology 1997;54: 508-15.
44. INK4 expression in non small cell lung carcinoma. Cancer 1997;80:389-95.
45. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74:535-9.
46. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 1998;79:71-5.
47. INK4A insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
48. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7.
49. Maelandsmo GM, Berner J-M, Flørenes VA, Forus A, Hovig E, Fodstad Ø, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995;72:393-8.